Going Global Is No Longer a 'Plan B': This Training Tackles Systemic Challenges in Biotech Overseas Financing
VCBeat
Internet Medical Health Media
The Global Biopharmaceutical Industry Is Undergoing Historic Transformation, and Chinese Biotech Companies Are Entering a Critical Breakthrough Period!
In May this year, an announcement drew global attention in the pharmaceutical industry: 3SBio licensed its clinical-stage PD-1/VEGF bispecific antibody candidate to Pfizer for an upfront payment of $1.25 billion, with a total deal value of $6.05 billion, setting a new record for Chinese innovative drugs going global. Shortly thereafter, on June 2, PM8002, a PD-L1/VEGF bispecific antibody developed by Promab Biotechnologies, was acquired by BioNTech and then sublicensed to Bristol Myers Squibb (BMS) for a staggering $11.1 billion, achieving a five-fold increase in valuation. These two consecutive blockbuster deals dominated financial and pharmaceutical headlines, igniting capital market enthusiasm for Chinese biotech companies.
In the current global environment of tightening resources and increasingly prudent investment,Going global is no longer a “backup plan only when funding runs dry,” but is increasingly becoming the strategic mainstream for navigating around capital cycles., it is an industrial resonance behavior driven by synergy and connectivity. Biotech has never been a single-track game reliant on one “blockbuster” product; rather, it is a multi-dimensional systemic operation requiring the coordinated alignment of talent, capital, pipelines, and production capacity!
But how should biotech companies precisely “put pen to paper” on the narrative of global expansion, which requires coordination and connectivity?
On one hand, enterprises often lack a systematic understanding of the entire cross-border financing process, leading to frequent legal and intellectual property disputes, as well as common mismatches between pipeline design and international clinical standards. On the other hand, the dual pressures of a domestic capital winter and tightening overseas policies have made it difficult for many biotech companies to clear financing hurdles, even with high-quality pipelines in hand. These pain points not only test a company’s technological prowess but also impose higher demands on its strategic planning, compliance capabilities, and resource integration.
Starting in 2024, VCBeat launched the “Practical Training Series on Overseas Financing for Chinese Biotech Companies in 2025”, successfully navigated throughBeijing, Suzhou, and Shenzhen hosted the event, with over 200 attendees including NewCo model operators, partners from top-tier USD funds, cross-border legal experts, executives from successfully funded enterprises, and heads of MNC Business Development., focusing on core topics such as end-to-end practical operations for overseas financing, legal and intellectual property risk mitigation, international tax planning, MNC project selection criteria, and global clinical development strategies. Through case studies and practical simulations, the event aims to provide Chinese pharmaceutical companies with systematic solutions ranging from strategy to implementation, helping them gain a competitive edge in the global market.
July 23–24Shanghai · Kangda Source Valley
2025 Practical Training on Overseas Fundraising for Chinese Biotech Companies
Don't Miss
Training Content
0
1
From0-1 Systematic Explanation：In-Depth Analysis of the NewCo Model
Niu Capital and enterprises practicing the NewCo model will conduct an in-depth analysis of the origins and evolution of the NewCo model, and share practical implementation strategies through real-world case studies.
0
2
Demand-Side Perspective: andFace-to-Face with MNCs and USD Funds
This training will analyze the strategic layouts and collaboration needs of multinational corporations (MNCs) from the perspective of demand-side stakeholders, while interpreting the investment preferences and decision-making processes of USD-denominated funds. Enterprises will have the opportunity to engage directly with potential partners to understand their expectations and concerns, thereby increasing the success rate of fundraising.
0
3
Key Process Steps: Legal Firms and Tax Experts Provide Support
Renowned law firms and tax experts will be present on-site, addressing key legal compliance issues, contract clauses, international tax regulations, intellectual property protection, and cross-border transaction risk mitigation. They will help enterprises build a robust legal defense to ensure a smooth and uninterrupted financing process.
0
4
CommunicationGala Dinner: Engage Directly with Industry Leaders, Speak Freely, and Get Your Questions Answered
The training program specially features an industry networking dinner with structured open-discussion sessions, offering participants the opportunity to engage in-depth with industry leaders, peer elites, and potential partners, thereby broadening their horizons and establishing more extensive collaborative relationships.
Training Agenda
Training Outline
1. Opportunities and Challenges for Biotech Companies in Overseas Financing (NewCo)
(1) Global Biotech Company Financing Overview
(2) Overseas Financing by Chinese Biotech Companies
(3) Sharing of Success Stories Under the NewCo Innovation Model
(4) Opportunities and Challenges for Chinese Biotech Companies in Overseas Fundraising
2. Logical Architecture and End-to-End Practical Implementation of the NewCo Model
(1) Strategic Analysis of NewCo’s Global Expansion Model
(2) Building NewCo from Scratch: Strategic Logic and Architectural Design
(3) A Comprehensive Analysis of the Practical Implementation Process for the NewCo Model
3. Common Tax Considerations and Optimization for Cross-Border Transactions of Life Sciences Companies Expanding Overseas
(1) Life Sciences and Pharmaceutical Enterprises: Key Tax Considerations in Licensing Transactions
(2) U.S. Tax Considerations for Life Sciences Companies – Licensing Transactions
4. How Chinese Biotech Companies Can Properly Mitigate Legal Risks in Cross-Border BD and Overseas Financing Transactions
(1) Common Forms of Overseas Financing Transactions for Chinese Biotech Companies (NewCo Model, BD Deals)
(2) Differences in the China-U.S. Agreement
(3) Legal Risks in Overseas Financing Transactions for Chinese Biotech Companies
(4) Practical Case Analysis: How to Properly Avoid Legal Risks in International Transactions
5. How Chinese Biotech Companies Address Intellectual Property Issues in Cross-Border Transactions
(1) Forms of Intellectual Property Collaboration in Cross-Border Transactions for Chinese Biotech Companies
(2) Common Intellectual Property Issues in Cross-Border Transactions Involving Chinese Biotech Companies
(3) How Chinese Biotech Companies Can Maximize the Protection of Their Intellectual Property
(4) IP and Patent Challenge Strategies for Cross-Border Transactions of Chinese Biotech Companies
6. Sharing Experiences in Global Operations for Enterprises in the Medical and Elderly Care Industries
(1) Establishment of Offshore Structure
(2) Overseas Account Selection
(3) Overseas Fund Management
(4) Cross-Border Financing Methods
(5) Overseas (Hong Kong, United States) Listing Strategy
7. Practical Insights from NewCo Operators
(1) How I Built NewCo
(2) Key Factors for NewCo’s Success
(3) How I Climbed Out of the Pitfalls I Encountered
8. Selection Criteria for Investment Projects of USD Funds
(1) Analysis of the Most Popular Sectors/Projects for USD-Denominated Funds
(2) Specific Process and Criteria for Project Screening by USD-Denominated Funds
(3) How to Negotiate Cooperation with USD-Denominated Funds
9. Criteria and Direction for MNC Project Selection
(1) Analysis of the Current Investment Status and Direction of MNCs
(2) Specific Processes and Criteria for MNC Project Screening
(3) How to Negotiate Collaborations with MNCs
10. Clinical Strategies for Chinese Biotech Companies to Pursue Internationalization
(1) What kind of clinical data is more favored by overseas investors?
(2) Clinical Protocol Strategy and Design for International Projects
Training Registration
Scan the QR Code to Register
Lock in Your Early Bird Spot
Scan the QR code to add Huimin from VCBeat
15111945514 (same as WeChat)
*Training Fee: RMB 1,999 per person (early bird rate of RMB 1,699 per person for registrations before July 15); group rate of RMB 1,499 per person for three or more participants. The fee includes lunch and a networking dinner. No refunds will be issued within three days prior to the start of the training.*
Previous Guests
Previous Attendees and Registered Companies
Hansoh Pharmaceutical International Business Department BD
Aisikang Biopharmaceuticals | Legal & IP
Astek Biopharmaceuticals Head of Financing
Renjing Biologics BD
Gaobo Medical Group BD
iX Biopharm BD
Changfeng Pharmaceutical Co., Ltd. Deputy General Manager
Wentao Innovative Drugs, General Manager
Puyou Bio CEO
Puyou Biotech Legal
Puyou Biologics Finance Manager
Dali Capital Partner
Director of Business Development, Shanghai Abbisko Bioscience
Shanghai Langsheng SVP
Clover Biopharmaceuticals · Head of Capital Markets
CEO of Shanghai Shimai Medical Technology Co., Ltd.
Yinglv Medical Technology Co., Ltd. Chief Executive Officer
Suzhou Furong Bio, Business Development Manager
Suzhou City University Master’s Supervisor
Transcenta Holding Business Development
Suzhou Fenchuang Zhigu Technology Co., Ltd. General Manager
Yunnan General Practice Trading Co., Ltd. Vice President of Sales
Lidi (Hangzhou) Pharmaceutical CEO
Sanyou Biologics Sales Department
Ribo Life Sciences CFO
Langxin Biotech Director of Financing
Depu Shi (Hangzhou) Biotech Co-Founder
Beijing Xinglin Kangyun CFO
Dawan Biotech BD Director
Soochow Securities Business Director
Pharmaron Executive Director, Legal Department
Fasheng Capital Director
Ideasurges (Beijing) Pharmaceutical BD
Beijing Qimiao Yongxian Gene & Cell Industry Incubation, Vice President
Nanjing Anji Biotechnology Co-Founder
Geek Gene COO & CBO
Sai Luo Bio BD
Beijing Fangzhou Baixin BD Director
Changxing Biotech BD Manager
Changxing Biotech Finance Manager
Weikang Pingsheng Product Director
IQVIADirector of Business Development, Clinical Trials Department
BeGene Senior Director, Government Affairs
Hode Biotech CEO
Beijing Zhenzhi Medical Business Development
Sunshine Noah & He, Deputy General Manager
Beite Pharmaceutical BD
Guanshi Capital Partner
Shaanxi Micaut Biotech Business Development
Kejun Pharma Head of Finance and Business Development
Zhejiang Ganaiwei Medical, Chairman
Gelu Capital Partner
Citibank, Vice President, Commercial Banking Division
MedSci Health BD
Shanghai Shimai Medical Technology Co., Ltd. CEO
Yinglv Medical Technology Co., Ltd. Chief Executive Officer
Chuanxin Bio BD
Zhongmei Ruikang, Head of Capital Markets and Finance
San You Bio Sales Department
Founder, Xizhao Consulting
Dawan Bio BD Director
Fosun Pharma, Project Manager, Project Management Department
Sai Mo Luo Biotech BD
CCB Equity Investment Business Director
Director, Shanghai Biomedical Technology Industry Promotion Center
Kemeixin Biotech CEO
Bayer SR BD MANAGER
Shanghai Junshi Assistant to the General Manager
Montaep Corporate Manager
Vice President, Arno Therapeutics
Hangzhou Anuwa Biopharmaceutical Technology Co., Ltd. Director
HSBC China Director
Rehab Capital, Director of Investment Analysis
Fujian Capital, Investment Director
Sequoia Capital China vp
Pivotal bioVenture Partners China / Investment Analyst
Director, China Medical Equipment
Fosun Pharma Asset Operations
Jemincare Senior Manager, Product BD
Boxiao Biotech, Deputy General Manager
Founder of the Guangdong-Macao Cooperation Chinese Medicine Science and Technology Industrial Park
VCBeat Senior Medical Manager
Yishan Capital Partner
GHC MD
Yishan Capital Partner
Jingze Biotech, Pharmaceutical Development Planning Department
Genecast Medical BD
Asymchem Employee
Mycro Bio Investment - CEO
Yinuo Pharmaceutical Vice President
VCBeat Capital · Heyi People
CCB Equity Investment Director
TEDA Capital Investment · Medical Investment Department
Shanghai Asymchem Biologics Manager
Xiangyao Bio BD Manager
Xiangyao Bio Business Manager
Xiangyao Bio BD VP
InnoCare Pharma VP
Cutia Biologics Deputy Strategic Director
Haihe Asymchem Fund Investment Manager
Deputy Minister Midechip
Yudao Biotech Director
Haiju Biotech General Manager
Base Biologics AD
Index Capital Senior Manager
HuaiGe Capital Partner
Bosun Pharma, Assistant to the Chairman
Glimmer Gene CEO
Kang Shida Investment Manager
China Renaissance Director
GenScript Biotech Corporation Director of Strategic Business Development
United Future Private Equity Fund, Investment Director
Hansoh Pharmaceutical Export Business Manager
Zelgen Pharmaceuticals BD Director
Bohai Biotech, Director of Affairs
Hanmei Medical Product Manager
MegaRobo Technologies Director of Laboratory Management
Free Trade Zone Fund Deputy Director
Xishen Asset Project Director
Shanghai Target Health Union, Deputy Director
Shanghai Takang Lianyao Finance Manager
Shanghai Hanyuan Senior Investment Manager
Private Equity Investment
Starlink Peptide VP
Mumian Capital Investment Manager
Tongyuankang Pharmaceutical Vice President
Siqi Culture Media | Key Account Manager
Flagship Pioneering Analyst
Morningside Venture CapitalInvestment Manager
Zeltgen Pharma BD Director
Johnson & Johnson Regional Scientific Program Lead
China Resources Double-Crane Pharmaceutical Co., Ltd. Supervisor
Ideals BD
KeWang Pharma BD
Expedition Therapeutics BD
ImmuneOnco Head of BD
Fujian Capital, Investment Director
GeekGene COO & CBO
Huichuan Capital Partner
Xing Hao Pengbo, Project Management Manager
Jichuan Pharmaceutical, Vice General Manager
TBD Head
Yaotang Bio Senior BD
Yaotang Bio BD VP
CanSino Biologics Head of Business Development
TBD BDD
Novartis Search & Evaluation Director
Roche Pharmaceuticals (China) BD AD
CSPC Pharmaceutical Group BD VP
Langma Peak Ventures Partner
J.P. Morgan China Vice President
Huagai Capital Managing Director
China Resources Double-Crane CBO
Fuqing Asset Management President
Probe Capital Managing Director
Qingtong Capital IR